BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th
About BioLineRx
BioLineRx is a publicly-traded
biopharmaceutical development company. BioLineRx is dedicated to
building a portfolio of products for unmet medical needs or with
advantages over currently available therapies. BioLineRx’s current
portfolio consists of seven clinical stage candidates: BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s
Source:
KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com
or
Todd
Fromer, 1-212-896-1250
tfromer@kcsa.com
or
Tsipi
Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il